Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

COALIZAO ACTION
 
NCT04394377
RCTanticoagulant, curative dosecontrolCOVID 19 hospitalizedsome concern
311/304 inconclusive
    COALIZAO ACTION
     
    NCT04394377
    RCTanticoagulant, curative doseanticoagulant, prophylactic doseCOVID 19 hospitalizedsome concern
    311/304 inconclusive

      COVID-19 mild to moderate meta-analysis

      ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients)
       
      NCT02735707
      RCTanticoagulant, curative dosecontrolCOVID-19 mild to moderatesome concern
      1190/1054 conclusif
      • demonstrated 27 % increase in clinical improvement (28-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
      atypical endpoints without correspondence with those of the others trials
      ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients)
       
      NCT02735707
      RCTanticoagulant, curative doseanticoagulant, prophylactic doseCOVID-19 mild to moderatesome concern
      1190/1054 conclusif
      • demonstrated 27 % increase in clinical improvement (28-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
      atypical endpoints without correspondence with those of the others trials
      RAPID (Sholzberg)
       
      NCT04362085
      RCTheparin at therapeutic dosestandard of careCOVID-19 mild to moderatesome concern
      228/237 suggested
      • suggested 78 % decrease in deaths,death D28 with a moderate degree of certainty due to some concern in risk of bias
      • inconclusive 31 % decrease in clinical deterioration (PE) with a moderate degree of certainty due to some concern in risk of bias

      COVID-19 severe or critically meta-analysis

      COVID-PACT RCTanticoagulant, curative doseanticoagulant, prophylactic doseCOVID-19 severe or criticallysome concern
      191/191 suggested
      • suggested 44 % decrease in Major thrombotic events or death (PE) with a moderate degree of certainty due to some concern in risk of bias
      INSPIRATION
       
      NCT04486508
      RCTanticoagulation, intermediate prophylactic dosecontrolCOVID-19 severe or criticallysome concern
      276/286 inconclusive
      • inconclusive 7 % increase in Thromboembolic events (PE) with a moderate degree of certainty due to some concern in risk of bias
      INSPIRATION
       
      NCT04486508
      RCTanticoagulation, intermediate prophylactic doseanticoagulant, prophylactic doseCOVID-19 severe or criticallysome concern
      276/286 inconclusive
      • inconclusive 7 % increase in Thromboembolic events (PE) with a moderate degree of certainty due to some concern in risk of bias
      REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients)
       
      NCT02735707
      RCTanticoagulant, curative dosecontrolCOVID-19 severe or criticallysome concern
      591/616 inconclusive
      • inconclusive 17 % decrease in clinical improvement (PE) with a moderate degree of certainty due to some concern in risk of bias
      REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients)
       
      NCT02735707
      RCTanticoagulant, curative doseanticoagulant, prophylactic doseCOVID-19 severe or criticallysome concern
      591/616 inconclusive
      • inconclusive 17 % decrease in clinical improvement (PE) with a moderate degree of certainty due to some concern in risk of bias
      5 studies excluded by filtering options (0 RCT / 5 OBS)

      PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
      Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).